Type:Tablet
Generic Name:Vildagliptin
Manufacturer:Concord Pharmaceuticals Ltd.
Price:৳0.00
Type 2 DM
May be taken with or without food.
Oral Type 2 diabetes mellitus Adult: 50 mg bid. Not recommended to use >100 mg/day. W/ metformin or a thiazolidinedione: 50 mg twice daily; w/ a sulfonylurea: 50 mg/day in the morning.
Renal impairment: Moderate, severe and ESRD: 50 mg once daily.
Hypersensitivity to vildagliptin
Vildagliptin is a dipeptidylpeptidase-4 (DPP-4) inhibitor that improves glycaemic control by preventing DPP-4 from inactivating the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thus prolonging incretin activity in response to ingestion of nutrients. This increases insulin sensitivity, decreases glucagon secretion and improves ?-cell function.
Patient w/ cardiac failure (NYHA functional class IV), type 1 DM; history of acute pancreatitis. Not intended for the treatment of diabetic ketoacidosis. Hepatic impairment, including patients w/ pre-treatment ALT or AST >3 times the upper limit of normal (ULN). Moderate or severe renal impairment, ESRD. Monitoring Parameters Monitor liver function.
Nausea, peripheral oedema, headache, tremor, asthenia, dizziness, constipation, hypoglycaemia, arthralgia, hepatic dysfunction, nasopharyngitis, upper resp tract infection, pancreatitis, exfoliative and bullous skin reactions.
Decreased hypoglycaemic effect w/ thiazides, corticosteroids, thyroid products and sympathomimetics.
